ProKidney Corp (PROK)
NASDAQ (CM) NASDAQ (CM) Primary 
XMEX Summary
PROK Chart
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results and business highlights for the year ended December 31, 2024.
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
ProKidney Corp Dividends
ProKidney Corp Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 17 Mar 2025 Date | | - Cons. EPS | - EPS |
| 10 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 14 May 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 17 Mar 2025 Date | | - Cons. EPS | - EPS |
| 10 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 14 May 2024 Date | | - Cons. EPS | - EPS |
ProKidney Corp (PROK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProKidney Corp ever had a stock split?
ProKidney Corp Profile
| Biotechnology Industry | Healthcare Sector | Dr. Bruce Culleton M.D. CEO | NASDAQ (CM) Exchange | KYG7S53R1049 ISIN |
| US Country | 204 Employees | - Last Dividend | - Last Split | 12 Jul 2022 IPO Date |
Overview
ProKidney Corp. is a pioneering entity in the biotechnology sector, focusing its efforts on the advancement of cell therapy platforms aimed at the amelioration of chronic kidney diseases. With its inception in 2015, the company has dedicated itself to developing innovative therapeutic solutions from its headquarters in Winston-Salem, North Carolina, USA. The primary mission of ProKidney Corp. is to introduce groundbreaking treatments that offer hope and improved outcomes for patients suffering from various kidney ailments, leveraging the vast potential of cell therapy technologies.
Products and Services
- Renal Autologous Cell Therapy (REACT):
This flagship product embodies the core of ProKidney Corp.'s innovative approach towards tackling chronic kidney diseases. REACT is a cutting-edge therapeutic modality based on the use of autologous homologous cell admixtures. This treatment has successfully completed its Phase I clinical trial, targeting patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Building upon this initial success, REACT has progressed to Phase III and Phase II clinical trials for addressing moderate to severe diabetic kidney disease, highlighting its potential as a transformative solution for a widespread and impactful health challenge.
Contact Information
